Table 1.
Characteristics of patients in this study.
| Characteristics n (%) | PL ( n = 32 ) | PR ( n = 29 ) | P-value |
|---|---|---|---|
| Age | 0.319 | ||
| ≥50 | 21 (65.6) | 14 (48.3) | |
| <50 | 11 (34.4) | 15 (51.7) | |
| Gender | 0.616 | ||
| Male | 29 (90.6) | 26 (89.7) | |
| Female | 3 (9.4) | 3 (10.3) | |
| ECOG PS | 0.797 | ||
| 0 | 9 (28.1) | 6 (20.7) | |
| 1 | 11 (34.4) | 11 (37.9) | |
| 2 | 12 (37.5) | 12 (41.4) | |
| Child-Pugh | 0.289 | ||
| A | 26 (81.3) | 26 (89.7) | |
| B | 6 (18.8) | 3 (10.3) | |
| ALBI | 0.09 | ||
| 1 | 7 (21.9) | 12 (41.4) | |
| 2 | 24 (75.0) | 14 (48.3) | |
| 3 | 1 (3.1) | 3 (10.3) | |
| BCLC | 0.562 | ||
| B | 9 (28.1) | 6 (20.7) | |
| C | 23 (71.9) | 23 (79.3) | |
| Aetiology of HCC | 0.199 | ||
| HBV | 28 (87.5) | 22 (75.9) | |
| Non-HBV, non-HCV | 4 (12.5) | 7 (24.1) | |
| Liver cirrhosis | 0.130 | ||
| YES | 27 (84.4) | 20 (69) | |
| NO | 5 (15.6) | 9 (31) | |
| Portal vein tumor thrombus | 0.183 | ||
| YES | 11 (34.4) | 6 (20.7) | |
| NO | 21 (65.6) | 23 (79.3) | |
| Extrahepatic spread | 0.123 | ||
| YES | 20 (62.5) | 23 (79.3) | |
| NO | 12 (37.5) | 6 (20.7) | |
| Combination of TACE | 0.366 | ||
| YES | 19 (59.4) | 15 (51.7) | |
| NO | 13 (40.6) | 14 (48.3) | |
| Baseline AFP ng/mL | 0.439 | ||
| ≥400 | 10 (31.3) | 13 (44.8) | |
| <400 | 22 (68.7) | 16 (55.2) | |
| Median treatment duration of sorafenib | 4.7 (3.5-6.0) | 3.9 (1.0-4.5) | 0.156 |
PL, PD-1 inhibitors plus lenvatinib; PR, PD-1 inhibitors plus regorafenib;BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group Performance status; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; ALBI, albumin-bilirubin.